Half-life of approximately 100 days increases likelihood of once-per-year dosing
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Seeking Alpha / 6 hours ago 1 Views
Seeking Alpha / 6 hours ago 1 Views
Half-life of approximately 100 days increases likelihood of once-per-year dosing
Comments